|Heron Therapeutics, Inc.|
123 Saginaw Drive
United States - Map
Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The companys lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
|Heron Therapeutics, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Barry D. Quart Pharm.D.,
Chief Exec. Officer and Director
|Mr. Robert H. Rosen ,
Pres and Director
|Mr. Brian G. Drazba CPA,
Chief Financial Officer and VP of Fin.
|Mr. Paul G. Marshall ,
Sr. VP of Technical Operations
|Ms. EsmÃ© C. Smith J.D.,
VP, Gen. Counsel and Sec.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|